22 December 2025VideosAmericasMicheal Hebert, Greenberg Traurig | Chuck Sholtz, Verdiva Bio | Josh Mack, Halozyme | Lawrence Rozsnyai, Metsera

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

WATCH: Clinical trials and their impact on patentability in Europe

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

SCOTUS shuts the door on Entresto ‘after-arising technology’ review

Morgan Lewis continues coast-to-coast US expansion with life sciences specialist

WATCH: Behind the scenes of big ticket litigation — lessons from the courts

Beyond traditional IP: A comprehensive AI strategy for life sciences

Winston & Strawn and Taylor Wessing UK plan transatlantic combo

Teva scrubs 200-plus Orange Book patents after FTC turns the screw

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

Editor's picks

Editor's picks

More features